Additionally, a bsAB targeting FLT3 and CD3 was developed on the basis of the FLYSYN mAB and exhibited enhanced cellular cytotoxicity against FLT3-expressing AML cells in comparison to the mAB alone [75]. Here, FLT3 is linked to acute myeloid leukemia.